Metabolic disease outfit accuses Chinese biotech of stealing trade secrets to advance competing drug
NASH is a big indication with plenty of benefits to the first company that can successfully get a working drug on the market. And according to one US biotech, a Chinese company stole trade secrets in order to get a head start.
Viking Therapeutics is suing Chinese biotech Ascletis Pharma in California district court, claiming that Ascletis essentially duped the biotech into divulging its trade secrets to the company and gave Ascletis the opportunity to release its own drug product to directly compete with Viking.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.